Nishidate Toshihiko, Katagiri Toyomasa, Lin Meng-Lay, Mano Yuria, Miki Yoshio, Kasumi Fujio, Yoshimoto Masataka, Tsunoda Tatsuhiko, Hirata Koichi, Nakamura Yusuke
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Int J Oncol. 2004 Oct;25(4):797-819.
Breast carcinoma is a complex disease characterized by accumulation of multiple genetic alterations, and the understanding of the molecular basis of mammary tumorigenesis is still incomplete. In this study we analyzed gene-expression profiles of 81 surgical specimens of 12 ductal carcinoma in situ (DCIS) and 69 invasive ductal carcinoma (IDC). After applying laser-microbeam micro-dissection to all samples we achieved 98-99% pure populations of breast cancer cells, and of normal breast epithelial cells used as controls. A cDNA-microarray analysis of 23,040 genes in these samples and a subsequent unsupervised hierarchical clustering distinguished two tumor groups, mainly in terms of estrogen-receptor (ER) status. We then undertook a supervised analysis and identified 325 genes that were commonly either up- or down-regulated in both pathologically discrete stages (DCIS and IDC), indicating that these genes might play important roles in malignant transformation of breast ductal cells. In addition, we searched invasion-associated gene candidates whose expression was altered in IDC, but not in DCIS, and identified 24 up-regulated genes and 41 down-regulated genes. Furthermore, we identified 34 genes that were expressed differently in tumors from patients with lymph node metastasis as opposed to no metastasis. On that basis we developed a scoring system that correlated well with the metastatic status. Tumors from all of the 37 test patients with lymph-node metastasis yielded positive scores by our definition, whereas 38 of the 40 tumors (95%) without lymph node metastasis had negative scores. Our data should provide useful information for identifying predictive markers for invasion or metastasis, and suggest potential target molecules for treatment of breast cancers.
乳腺癌是一种复杂的疾病,其特征是多种基因改变的积累,而对乳腺肿瘤发生分子基础的理解仍不完整。在本研究中,我们分析了12例导管原位癌(DCIS)和69例浸润性导管癌(IDC)的81个手术标本的基因表达谱。在对所有样本应用激光微束显微切割后,我们获得了98%-99%的纯乳腺癌细胞群体以及用作对照的正常乳腺上皮细胞群体。对这些样本中的23,040个基因进行cDNA微阵列分析以及随后的无监督层次聚类区分出两个肿瘤组,主要依据雌激素受体(ER)状态。然后我们进行了有监督分析,鉴定出325个在两个病理上不同阶段(DCIS和IDC)均普遍上调或下调的基因,表明这些基因可能在乳腺导管细胞的恶性转化中起重要作用。此外,我们搜索了在IDC中表达改变但在DCIS中未改变的侵袭相关基因候选物,鉴定出24个上调基因和41个下调基因。此外,我们鉴定出34个在有淋巴结转移患者的肿瘤与无转移患者的肿瘤中表达不同的基因。在此基础上,我们开发了一种与转移状态相关性良好的评分系统。按照我们的定义,所有37例有淋巴结转移的测试患者的肿瘤均获得阳性评分,而40例无淋巴结转移的肿瘤中有38例(95%)获得阴性评分。我们的数据应为识别侵袭或转移的预测标志物提供有用信息,并为乳腺癌治疗提示潜在的靶分子。